removed the SBIAB indication from its labeling, consistent with this decision. In addition, FDA will continue to accept and, where appropriate, approve ANDAs that refer to CECLOR CD (cefaclor extended-release tablets) as long as they meet relevant legal and regulatory requirements, but FDA will not accept or approve ANDAs that refer to this drug product and propose to include the SBIAB indication. If FDA determines that labeling for this drug product should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.

Dated: July 20, 2021.

Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.

[FR Doc. 2021–16050 Filed 7–27–21; 8:45 am]
BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. FDA–2021–N–0698]

Outsourcing Facility Fee Rates for Fiscal Year 2022

AGENCY: Food and Drug Administration, Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the fiscal year (FY) 2022 rates for the establishment and reinspection fees related to entities that compound human drugs and elect to register as outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FD&C Act authorizes FDA to assess and collect an annual establishment fee from outsourcing facilities, as well as a reinspection fee for each reinspection of an outsourcing facility. This document establishes the FY 2022 rates for the small business establishment fee ($5,824), the non-small business establishment fee ($18,999), and the reinspection fee ($17,472) for outsourcing facilities; provides information on how the fees for FY 2022 were determined; and describes the payment procedures outsourcing facilities should follow. These fee rates are effective October 1, 2021, and will remain in effect through September 30, 2022.

FOR FURTHER INFORMATION CONTACT: For more information on human drug compounding and outsourcing facility fees: Visit FDAs website at: https://www.fda.gov/Drugs/ComplianceEnforcement/Pharmacy/Compounding/default.htm.


SUPPLEMENTARY INFORMATION:

I. Background

Under section 503B of the FD&C Act (21 U.S.C. 353b), a human drug compounder can become an “outsourcing facility.” Outsourcing facilities, as defined in section 503B(d)(4), are facilities that meet all the conditions described in section 503B(a), including registering with FDA as an outsourcing facility and paying an annual establishment fee. If the conditions of section 503B are met, a drug compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility is exempt from three sections of the FD&C Act: (1) Section 502(f)(1) (21 U.S.C. 352(f)(1)) concerning the labeling of drugs with adequate directions for use; (2) section 505 (21 U.S.C. 355) concerning the approval of human drug products under new drug applications (NDAs) or abbreviated new drug applications (ANDAs); and (3) section 582 (21 U.S.C. 360ee–1) concerning drug supply chain security requirements. Drugs compounded in outsourcing facilities are not exempt from the requirements of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)) concerning current good manufacturing practice requirements for drugs.

Section 744K of the FD&C Act (21 U.S.C. 379j–62) authorizes FDA to assess and collect the following fees associated with outsourcing facilities:

1) An annual establishment fee from each outsourcing facility and
2) a reinspection fee from each outsourcing facility subject to a reinspection (see section 744K(a)(1) of the FD&C Act).

Under statutorily defined conditions, a qualified applicant may pay a reduced small business establishment fee (see section 744K(c)(4) of the FD&C Act).

FDA announced in the Federal Register of November 24, 2014 (79 FR 69856), the availability of a final guidance for industry entitled “Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act.” The guidance provides additional information on the annual fees for outsourcing facilities and adjustments required by law, reinspection fees, how to submit payment, the effect of failure to pay fees, and how to qualify as a small business to obtain a reduction of the annual establishment fee. This guidance can be accessed on FDA’s website at: https://www.fda.gov/media/136683/download.

II. Fees for FY 2022

A. Methodology for Calculating FY 2022 Adjustment Factors

1. Inflation Adjustment Factor

Section 744K(c)(2) of the FD&C Act specifies the annual inflation adjustment for outsourcing facility fees. The inflation adjustment has two components: One based on FDA’s payroll costs and one based on FDA’s non-payroll costs for the first 3 of the 4 previous fiscal years. The payroll component of the annual inflation adjustment is calculated by taking the average change in FDA’s per-full-time equivalent (FTE) personnel compensation and benefits (PC&B) in the first 3 of the 4 previous fiscal years (see section 744K(c)(2)(A)(ii) of the FD&C Act). FDA’s total annual spending on PC&B is divided by the total number of FTEs per fiscal year to determine the average PC&B per FTE.

Table 1 summarizes the actual cost and FTE data for the specified fiscal years, and provides the percent change from the previous fiscal year and the average percent change over the first 3 of the 4 fiscal years preceding FY 2022. The 3-year average is 2.7383 percent.

<table>
<thead>
<tr>
<th>Fiscal year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>3-Year average</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total PC&amp;B</td>
<td>$2,690,678,000</td>
<td>$2,620,052,000</td>
<td>$2,875,592,000</td>
<td></td>
</tr>
<tr>
<td>Total FTE</td>
<td>17,023</td>
<td>17,144</td>
<td>17,535</td>
<td></td>
</tr>
<tr>
<td>PC&amp;B per FTE</td>
<td>$158,061</td>
<td>$152,826</td>
<td>$163,992</td>
<td></td>
</tr>
<tr>
<td>Percent change from previous year</td>
<td>4.2206</td>
<td>–3.3120</td>
<td>7.3063</td>
<td>2.7383</td>
</tr>
</tbody>
</table>
Section 744K(c)(2)(A)(ii) of the FD&C Act specifies that this 2.7383 percent should be multiplied by the proportion of PC&B to total costs of an average FDA FTE for the same 3 fiscal years.

### Table 2—FDA PC&Bs as a Percent of FDA Total Costs of an Average FTE

<table>
<thead>
<tr>
<th>Fiscal year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>3-Year average</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total PC&amp;B</td>
<td>$2,690,678,000</td>
<td>$2,620,052,000</td>
<td>$2,875,592,000</td>
<td></td>
</tr>
<tr>
<td>Total Costs</td>
<td>$5,370,935,000</td>
<td>$5,663,389,000</td>
<td>$6,039,321,000</td>
<td></td>
</tr>
<tr>
<td>PC&amp;B Percent</td>
<td>50.0970</td>
<td>46.2630</td>
<td>47.6145</td>
<td>47.9915</td>
</tr>
</tbody>
</table>

The payroll adjustment is 2.7383 percent multiplied by 47.9915 percent, or 1.3142 percent.

Section 744K(c)(2)(A)(ii) of the FD&C Act specifies that the proportion of the inflation adjustment for non-payroll costs for FY 2022 is equal to the average annual percent change in the Consumer Price Index (CPI) for urban consumers (U.S. City Average; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data, multiplied by the proportion of all non-PC&B costs to total costs of an average FDA FTE for the same period.

Table 2 provides the summary data for the percent change in the specified CPI for U.S. cities. These data are published by the Bureau of Labor Statistics and can be found on its website: https://data.bls.gov/cgi-bin/surveymost?cu. The data can be viewed by checking the box marked “U.S. city average, All items—CUUR0000SA0” and then selecting “Retrieve Data.”

### Table 3—Annual and 3-Year Average Percent Change in U.S. City Average CPI

<table>
<thead>
<tr>
<th>Year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>3-Year average</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual CPI</td>
<td>251.107</td>
<td>255.657</td>
<td>258.811</td>
<td></td>
</tr>
<tr>
<td>Annual Percent Change</td>
<td>2.4425</td>
<td>1.8120</td>
<td>1.2337</td>
<td>1.8294</td>
</tr>
</tbody>
</table>

Section 744K(c)(2)(A)(ii) of the FD&C Act specifies that this 1.8294 percent should be multiplied by the proportion of all non-PC&B costs to all costs of an average FTE for the same 3 fiscal years. The proportion of all non-PC&B costs to total costs of an average FDA FTE for FYS 2018 to 2020 is 50.0970 percent (100 percent minus 47.9915 percent equal 52.0085 percent). Therefore, the non-pay adjustment is 1.8294 percent times 52.0085 percent, or 0.9514 percent.

The PC&B component (1.3142 percent) is added to the non-PC&B component (0.9514 percent), for a total inflation adjustment of 2.2656 percent (rounded). Section 744K(c)(2)(A)(i) of the FD&C Act specifies that one is added to that figure, making the inflation adjustment 1.022656.

Section 744K(c)(2)(B) of the FD&C Act provides for this inflation adjustment to be compounded after FY 2015. This factor for FY 2022 (2.2656 percent) is compounded by adding one to it, and then multiplying it by one plus the inflation adjustment factor for FY 2021 (1.022656 × 1.022656) becomes the inflation adjustment for FY 2022. For FY 2022, the inflation adjustment is 16.4796 percent (rounded). We then add one, making the FY 2022 inflation adjustment factor 1.164796.

2. Small Business Adjustment Factor

Section 744K(c)(3) of the FD&C Act specifies that in addition to the inflation adjustment factor, the establishment fee for non-small businesses is to be further adjusted for a small business adjustment factor. Section 744K(c)(3)(B) of the FD&C Act provides that the small business adjustment factor is the adjustment to the establishment fee for non-small businesses that is necessary to achieve total fees equaling the amount that FDA would have collected if no entity qualified for the small business exception in section 744K(c)(4) of the FD&C Act. Additionally, section 744K(c)(3)(A) states that in establishing the small business adjustment factor for a fiscal year, FDA shall provide for the crediting of fees from the previous year to the next year if FDA overestimated the amount of the small business adjustment factor for such previous fiscal year.

Therefore, to calculate the small business adjustment to the establishment fee for non-small businesses for FY 2022, FDA must estimate: (1) The number of outsourcing facilities that will pay the reduced fee for small businesses for FY 2022 and (2) the total fee revenue it would have collected if no entity had qualified for the small business exception (i.e., if each entity that registers as an outsourcing facility for FY 2022 were to pay the inflation-adjusted fee amount of $17,472). With respect to (1), FDA estimates that 12 entities will qualify for small business exceptions and will pay the reduced fee for FY 2022. With respect to (2), to estimate the total number of entities that will register as outsourcing facilities for FY 2022, FDA used data submitted by outsourcing facilities through the voluntary registration process, which began in December 2013. Accordingly, FDA estimates that 80 outsourcing facilities, including 12 small businesses, will be registered with FDA in FY 2022.

If the projected 80 outsourcing facilities paid the full inflation-adjusted fee of $17,472, this would result in total revenue of $1,397,760 in FY 2022 ($17,472 × 80). However, 12 of the entities that are expected to register as outsourcing facilities for FY 2022 are projected to qualify for the small business exception and to pay one-third of the full fee ($5,824 × 12), totaling $69,888 instead of paying the full fee ($17,472 × 12), which would total $209,664. This would leave a potential shortfall of $139,776 ($209,664 minus $69,888).

Additionally, section 744K(c)(5)(A) of the FD&C Act states that in establishing the small business adjustment factor for a fiscal year, FDA shall provide for the
crediting of fees from the previous year to the next year if FDA overestimated the amount of the small business adjustment factor for such previous fiscal year. FDA has determined that it is appropriate to credit excess fees collected from the last completed fiscal year, due to the inability to conclusively determine the amount of excess fees from the fiscal year that is in progress at the time this calculation is made. This crediting is done by comparing the small business adjustment factor for the last completed fiscal year, FY 2020 ($2,208), to what would have been the small business adjustment factor for FY 2020 ($1,671) if FDA had estimated perfectly.

The calculation for what the small business adjustment would have been if FDA had estimated perfectly begins by determining the total target collections \(15,000 \times \text{inflation adjustment factor} \times \text{number of registrants}\). For the most recent complete fiscal year, FY 2020, this was \$1,293,446 \(16,798 \times 77\). The actual FY 2020 revenue from the 77 total registrants (i.e., 67 registrants paying FY 2020 non-small business establishment fee and 10 small business registrants) paying establishment fees is \$1,181,456. \$1,181,456 is calculated as follows: (FY 2020 Non-Small Business Establishment Fee adjusted for inflation only) \(\times\) (total number of registrants in FY 2020 paying Non-Small Business Establishment Fee) + (FY 2020 Small Business Establishment Fee) \(\times\) (total number of small business registrants in FY 2020 paying Small Business Establishment Fee). \$16,798 \(\times 67\) + \$5,599 \(\times 10\) = \$1,181,456. This left a shortfall of \$111,990 from the estimated total target collection amount \(1,293,446 \text{ minus } 1,181,456\). This amount \(111,990\) divided by the total number of registrants in FY 2020 paying Standard Establishment Fee (67) equals \$1,671.

The difference between the small business adjustment factor used in FY 2020 and the small business adjustment factor that would have been used had FDA estimated perfectly is \$537 (\$2,208 minus \$1,671). The \$537 (rounded to the nearest dollar) is then multiplied by the number of actual registrants who paid the standard fee for FY 2020 (67), which provides us a total excess collection of \$35,963 in FY 2020.

Therefore, to calculate the small business adjustment factor for FY 2022, FDA subtracts \$35,963 from the projected shortfall of \$139,776 for FY 2022 to arrive at the numerator for the small business adjustment amount, which equals \$65,813. This number divided by 68 (the number of expected non-small businesses for FY 2022) is the small business adjustment amount for FY 2022, which is \$1,527 (rounded to the nearest dollar).

**B. FY 2022 Rates for Small Business Establishment Fee, Non-Small Business Establishment Fee, and Reinspection Fee**

1. Establishment Fee for Qualified Small Businesses

The amount of the establishment fee for a qualified small business is equal to \$15,000 multiplied by the inflation adjustment factor for that fiscal year, divided by 3 (see section 744K(c)(4)(A) and (c)(1)(A) of the FD&C Act). The inflation adjustment factor for FY 2022 is 1.164796. See section II.A.1 for the methodology used to calculate the FY 2022 inflation adjustment factor.

Therefore, the establishment fee for a qualified small business for FY 2022 is one third of \$17,472, which equals \$5,824 (rounded to the nearest dollar).

2. Establishment Fee for Non-Small Businesses

Under section 744K(c) of the FD&C Act, the amount of the establishment fee for a non-small business is equal to \$15,000 multiplied by the inflation adjustment factor for that fiscal year, plus the small business adjustment factor for that fiscal year, and plus or minus an adjustment factor to account for over or under collections due to the small business adjustment factor in the prior year. The inflation adjustment factor for FY 2022 is 1.164796. The small business adjustment amount for FY 2022 is \$1,527. See section II.A.2 for the methodology used to calculate the small business adjustment factor for FY 2022. Therefore, the establishment fee for a non-small business for FY 2022 is \$15,000 multiplied by 1.164796 plus \$1,527, which equals \$18,999 (rounded to the nearest dollar).

3. Reinspection Fee

Section 744K(c)(1)(B) of the FD&C Act provides that the amount of the FY 2022 reinspection fee is equal to \$15,000, multiplied by the inflation adjustment factor for that fiscal year. The inflation adjustment factor for FY 2022 is

\[1.164796\] therefore, the reinspection fee for FY 2022 is \$15,000 multiplied by 1.164796, which equals \$17,472 (rounded to the nearest dollar). There is no reduction in this fee for small businesses.

**C. Summary of FY 2022 Fee Rates**

<table>
<thead>
<tr>
<th>Table 4—Outsourcing Facility Fees</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Qualified Small Business Establishment Fee</strong></td>
</tr>
<tr>
<td><strong>Non-Small Business Establishment Fee</strong></td>
</tr>
<tr>
<td><strong>Reinspection Fee</strong></td>
</tr>
</tbody>
</table>

**III. Fee Payment Options and Procedures**

A. Establishment Fee

Once an entity submits registration information and FDA has determined that the information is complete, the entity will incur the annual establishment fee. FDA will send an invoice to the entity, via email to the email address indicated in the registration file, or via regular mail if email is not an option. The invoice will contain information regarding the obligation incurred, the amount owed, and payment procedures. A facility will not be registered as an outsourcing facility until it has paid the annual establishment fee under section 744K of the FD&C Act. Accordingly, it is important that facilities seeking to operate as outsourcing facilities pay all fees immediately upon receiving an invoice. If an entity does not pay the full invoiced amount within 15 calendar days after FDA issues the invoice, FDA will consider the submission of registration information to have been withdrawn and adjust the invoice to reflect that no fee is due.

Outsourcing facilities that registered in FY 2021 and wish to maintain their status as an outsourcing facility in FY 2022 must register during the annual registration period that lasts from October 1, 2021, to December 31, 2021. Failure to register and complete payment by December 31, 2021, will result in a loss of status as an outsourcing facility on January 1, 2022. Entities should submit their registration information no later than December 10, 2021, to allow enough time for review of the registration information, invoicing, and payment of fees before the end of the registration period.

B. Reinspection Fee

FDA will issue invoices for each reinspection after the conclusion of the reinspection, via email to the email address indicated in the registration file.
or via regular mail if email is not an option. Invoices must be paid within 30
days.

C. Fee Payment Procedures

1. The preferred payment method is
   online using electronic check
(automated clearing house (ach) also
known as e-check) or credit card
(discover, visa, mastercard, american
express). Secure electronic payments
can be submitted using the user fees
payment portal at—https://
userfees.fda.gov/pay. (note: only full
payments are accepted. no partial
payments can be made online.) once
you search for your invoice, click “pay
now” to be redirected to pay.gov.

Electronic payment options are based on
the balance due. Payment by credit card
is available for balances less than
$25,000. If the balance exceeds this
amount, only the ach option is
available. Payments must be made using
U.S. bank accounts as well as U.S. credit
cards.

2. If paying with a paper check:
   Checks must be in U.S. currency from
   a U.S. bank and made payable to the
   Food and Drug Administration.
   Payments can be mailed to: Food and
Drug Administration, P.O. Box 979033,
St. louis, MO 63197-9000. Include
invoice number on check. If a check is
available. Payments must be made using
U.S. bank accounts as well as U.S. credit

cards.

3. When paying by wire transfer, the
   invoice number must be included.
   Without the invoice number the
   payment may not be applied. Regarding
   reinspection fees, if the payment
   amount is not applied, the invoice
   amount will be referred to collections.
   The originating financial institution
   may charge a wire transfer fee. If the
   financial institution charges a wire
   transfer fee, it is required that the
   outsource facility add that amount to
   the payment to ensure that the invoice
   is paid in full. Use the following
   account information when sending a
   wire transfer: U.S. dept of the Treasury,
   treas ny, 33 liberty st., new york,
   NY 10045, acct. No. 75060099, routing
   No. 021030004, swift: FRNYUS33. If
   needed, FDA’s tax identification
   number is 53-0196965.

Dated: July 20, 2021.

Lauren K. Roth,
acting principal associate commissioner for
policy.

SUMMARY: the food and drug
administration (FDA or agency) is
withdrawing approval of 15 abbreviated
new drug applications (ANDAs) from
multiple applicants. the applicants
notified the agency in writing that the
drug products were no longer marketed
and requested that the approval of the
applications be withdrawn.

DATES: Approval is withdrawn as of
August 27, 2021.

FOR further information contact:
Martha Nguyenn, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
hampshire Ave., Bldg. 75, rm. 1676,
Silver spring, MD 20993-0002, 240-
402-6980, Martha.Nguyen@fda.hhs.gov.

C. Fee Payment Procedures

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Food and Drug Administration
[Docket No. FDA–2021–N–0652]

Fresenius Kabi USA, LLC, et al.;
Withdrawal of Approval of 15
Abbreviated New Drug Applications

agency: Food and Drug Administration.

HHS.

ACTION: Notice.

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Drug</th>
<th>Applicant</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA 040265</td>
<td>Methotrexate Sodium Injection, Equivalent to (EQ) 25 milligrams (mg) base/millimeters (mL).</td>
<td>Fresenius Kabi USA, LLC, Three Corporate Dr., Lake Zurich, IL 60047.</td>
</tr>
<tr>
<td>ANDA 070963</td>
<td>Clonidine Hydrochloride (HCl) Tablets, 0.3 mg</td>
<td>Watson Laboratories, Inc. (an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.), 400 Interpace Pkwy., Bldg. A, Parsippany, NJ 07054.</td>
</tr>
<tr>
<td>ANDA 074292</td>
<td>Dobutamine HCl Injection, EQ 12.5 mg base/mL</td>
<td>Hospira, Inc., 275 North Field Dr., Bldg. H1, Lake Forest, IL 60045.</td>
</tr>
<tr>
<td>ANDA 075069</td>
<td>Etdolac Tablets, 400 mg</td>
<td>Watson Laboratories, Inc.</td>
</tr>
<tr>
<td>ANDA 075856</td>
<td>Midazolam HCl Injection, EQ 1 mg base/mL and EQ 5 mg base/mL</td>
<td>Hospira, Inc.</td>
</tr>
<tr>
<td>ANDA 084504</td>
<td>Hydralazine HCl Tablets, 25 mg</td>
<td>Hospira, Inc.</td>
</tr>
<tr>
<td>ANDA 090379</td>
<td>Budesonide Delayed Release Capsules, 3 mg</td>
<td>Watson Laboratories, Inc.</td>
</tr>
<tr>
<td>ANDA 091590</td>
<td>Losartan Potassium Tablets, 25 mg, 50 mg, and 100 mg.</td>
<td>Barr Laboratories, Inc. (an indirect, wholly owned subsidiary of teva Pharmaceuticals USA, Inc.), 400 Interpace Pkwy., Bldg. A, Morris Corporate Center III, Parsippany, NJ 07054.</td>
</tr>
<tr>
<td>ANDA 091652</td>
<td>Hydrochlorothiazide and Losartan Potassium Tablets, 12.5 mg/50 mg, 12.5 mg/100 mg, and 25 mg/100 mg.</td>
<td>Mylan Pharmaceuticals Inc., a Viatris company, 81 Chestnut Ridge Rd., P.O. Box 4310, Morgantown, WV 26504.</td>
</tr>
<tr>
<td>ANDA 204361</td>
<td>Eptifibatide Injection, 2 mg/mL and 75 mg/100 mL</td>
<td>USV Private Limited, U.S. Agent, Omega Pharmaceutical Consulting, Inc., 752 West Shuhthagi Lane, New harmony, UT 84757.</td>
</tr>
<tr>
<td>ANDA 204362</td>
<td>Eptifibatide Injection, 2 mg/mL</td>
<td>USV Private Limited, U.S. Agent, Omega Pharmaceutical Consulting, Inc., 752 West Shuhthagi Lane, New harmony, UT 84757.</td>
</tr>
</tbody>
</table>